Search
Mirococept
go.drugbank.com/drugs/DB06492ExperimentalIt is a truncated form of the human Complement Receptor 1 (CR1) linked to a unique Prodaptin™ construct that regulates the over-production of complement at the cell surface, which occurs in inflammation … It consists of the first three short consensus domains of human complement receptor 1 (CR1), manufactured in recombinant bacteria and modified with a membrane-targeting amphiphilic peptide based on the
NOX-700
go.drugbank.com/drugs/DB05464ExperimentalNOX-700, an new orally active dithiocarbamate-based nitric oxide (NO) blocking agent that is in development for the treatment of diabetes mellitus (type 2 diabetes).
Ceftiofur
go.drugbank.com/drugs/DB11485ExperimentalVet approvedCeftiofur is a third generation cephalosporin antibiotic, first described in 1987, and now used in veterinary medicine. … It is marketed by pharmaceutical company Zoetis as Excenel, and is the active ingredient in that company's Specramast LC (lactating cow formula) product.
RUTI® Vaccine
go.drugbank.com/drugs/DB15853InvestigationalMuch like the BCG vaccine, the RUTI® vaccine is also being tested as a prophylactic for SARS-CoV2. … The vaccine has demonstrated a reasonable safety profile and potent stimulation of the immune response against tuberculosis.
TST10088
go.drugbank.com/drugs/DB05151ExperimentalTST10088 is a recombinant variant of a plant toxin belonging to the family of class II ribosome inactivating proteins. … These molecules efficiently kill cells by activating preprogrammed death pathways known as apoptosis.
PX-12
go.drugbank.com/drugs/DB05448InvestigationalSince high levels of Trx-1 have been associated with colorectal, gastric and lung cancers, PX-12 is indicated as a potential cancer treatment in combination with chemotherapy for patients with advanced … PX-12 (1-methylpropyl 2-imidazolyl disulfide) is a small-molecule inhibitor of Trx-1 (thioredoxin-1), stimulates apoptosis, down-regulates HIF-1α and vascular endothelial growth factor (VEGF) and inhibits
Gemtuzumab ozogamicin
go.drugbank.com/drugs/DB00056ApprovedInvestigationalGemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora … Marketing approval of gemtuzumab ozogamicin was granted on May 17, 2000 by FDA as a treatment for patients with CD33-positive AML in first relapse who are 60 years of age or older and who are not considered
ARC183
go.drugbank.com/drugs/DB05124ExperimentalARC183 is a DNA aptamer, which is a single-stranded DNA molecule consisting of 15 deoxynucleotides that forms well-defined three-dimensional configuration, allowing it to bind to thrombin with high affinity … The key advantage of ARC183 compared to other thrombin inhibitors is its rapid onset of action and short half-life, giving it the potential to be an ideal agent for medical procedures that require rapid
Inactivated SARS-Cov-2 Vaccine
go.drugbank.com/drugs/DB15862InvestigationalThis strain was isolated from a patient in Wuhan, cultivated in a Vero cell line, and then subsequently inactivated using B-propiolactone. … [A220158] Currently, the vaccine is being tested in Phase 3 clinical trial in Abu Dhabi (ChiCTR2000034780).[A219758]
Adakitug
go.drugbank.com/drugs/DB05484InvestigationalMDX-018, also known as HuMax-Inflam, is a fully human antibody that is directed to IL-8 (interleukin-8) and may have potential application in oncology and inflammation. … Trials will initially focus on studies to treat glioblastoma, a cancer of the central nervous system.